HyQvia® treatment is a 10% subcutaneous immunoglobulin treatment facilitated by recombinant human hyaluronidase. Learn more about HyQvia®'s mode of action and why this improves bioavailability. This innovative therapy utilizes a dosage interval every 2-4 weeks.^1,2

Helpful guide for subcutaneous immunoglobulins therapy start with our products Cuvitru® and HyQvia®. In this clickable brochure, you will find dosing and switch examples, main characteristics of the products and descriptions of patients that might benefit from a subcutaneous therapy.